Tandem Diabetes' 'rapid' growth can continue, says Piper Jaffray
Piper Jaffray analyst JP McKim reiterates an Overweight rating on Tandem Diabetes with a $78 price target after traveling with management. The company can continue its "rapid" growth though international expansion beyond Animas patients, McKim tells investors in a research note titled "Travel With Management Confirms 'Goldilocks Period' Set To Continue." Further, while Animas supplies stop September 2019, there will be patients who stock up on supplies into 2020 and also some of the patients who took the free MDT 630G in late 2017 will have their old Animas warranty expire and allow them to re-enter the pump market once again, adds the analyst. He also expects Tandem win market share.